Omega-3 polyunsaturated fatty acids protect human hepatoma cells from developing steatosis through FFA4 (GPR120)

This publication has 31 references indexed in Scilit:

• Docosahexaenoic acid for the treatment of fatty liver: Randomised controlled trial in children
  Nutrition, Metabolism and Cardiovascular Diseases, 2013
• The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
  Gastroenterology, 2012
• Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis
  Journal of Hepatology, 2012
• Mechanisms of Gene Regulation by Fatty Acids
  Advances in Nutrition, 2012
• Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human
  Nature, 2012
• GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects
  Cell, 2010
• Enhancement in liver SREBP-1c/PPAR-α ratio and steatosis in obese patients: Correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion
  Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
• Prolonged n‐3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non‐alcoholic fatty liver disease: a pilot study
  Alimentary Pharmacology & Therapeutics, 2006
• Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120
  Nature Medicine, 2004
• Effects of Prolonged Ethanol Intake: Production of Fatty Liver Despite Adequate Diets*
  Journal of Clinical Investigation, 1965